Dark Streaming/Mobile Old Site Home Daily Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
11:03:30 EDT Tue 21 Mar 2023
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:AMRN - AMARIN CORP ADR EACH REP 1 ORD GBP0.50 - http://www.amarincorp.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
AMRN - Q11.41.58·1.5914.01.585+0.0151.01,223.11,8747601.61  1.6575  1.5753.74  1.0410:42:33Mar 1615 min RT 2¢

Recent Trades - Last 10 of 760
Time ETExPriceChangeVolume
10:42:33Q1.5850.015400
10:42:11Q1.5850.015300
10:42:05Q1.5850.01510
10:41:04Q1.5950.025300
10:41:04Q1.590.021,300
10:41:04Q1.590.02600
10:41:04Q1.590.021,500
10:41:04Q1.590.021,500
10:41:04Q1.590.022,700
10:41:04Q1.590.02300

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2023-03-16 08:00U:AMRNNews ReleaseReconstituted Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA ‚ ®/VAZKEPA ‚ ® (Icosapent Ethyl)
2023-03-06 16:06U:AMRNNews ReleaseAmarin Announces Board Departures
2023-03-06 08:00U:AMRNNews ReleaseAmarin Highlights New Evidence of Therapeutic Value of EPA in Reducing Cardiovascular Events in At-Risk Patients Presented at ACC.23/WCC
2023-03-05 10:21U:AMRNNews ReleaseAmarin Announces New REDUCE-IT ‚ ® Data at ACC.23/WCC Showing Benefit of VASCEPA ‚ ®/VAZKEPA ‚ ® (Icosapent Ethyl) in High-Risk Patients with a Recent Acute Coronary Syndrome Event
2023-03-01 07:00U:AMRNNews ReleaseAmarin Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
2023-02-28 10:39U:AMRNNews ReleaseSarissa Capital Wins Proxy Contest Against Amarin by Huge Landslide
2023-02-28 10:38U:AMRNNews ReleaseAmarin Announces Preliminary Voting Results Following 2023 General Meeting of Shareholders
2023-02-28 08:01U:AMRNNews ReleaseAmarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA ‚ ® (Icosapent Ethyl) in Australia and New Zealand
2023-02-27 16:29U:AMRNNews ReleaseAmarin Sets the Record Straight on Sarissa ¢ € ™s Latest Misstatements
2023-02-27 08:00U:AMRNNews ReleaseAmarin Corporation to Present New Data Evaluating VASCEPA ‚ ®/VAZKEPA ‚ ® (Icosapent Ethyl) at ACC.23/WCC
2023-02-27 07:15U:AMRNNews ReleaseSarissa Capital Condemns Amarin Board for Frontrunning Results of Proxy Contest With Egregious Equity Grants to Executives
2023-02-22 08:00U:AMRNNews ReleaseAmarin to Present at Cowen's 43rd Annual Health Care Conference